The short-term study (6 months) is completed. The extension phase of the study is continuing with 36 women. The extension phase is an 18 month open-label study. Most women have elected to be treated with Raloxifene. This study has now been completed and data is being analyzed.
Showing the most recent 10 out of 638 publications